Published in Tumori on November 18, 1997
A conformal index (COIN) to evaluate implant quality and dose specification in brachytherapy. Int J Radiat Oncol Biol Phys (1998) 2.42
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemother Pharmacol (2010) 2.32
Radiation therapy for the prevention of heterotopic ossification at the elbow. J Bone Joint Surg Br (2001) 2.12
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol (1999) 1.98
Foreign body in the airways: a review of 90 cases. Arch Otolaryngol (1977) 1.89
Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat (2011) 1.87
CT-Based interstitial HDR brachytherapy. Strahlenther Onkol (1999) 1.58
Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg (2005) 1.55
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. Eur J Cancer (2008) 1.47
Cisplatin and continuous infusion of fluorouracil followed by radiation and weekly carboplatin in the treatment of locally advanced head and neck cancer: a Hellenic Cooperative Oncology Group study. Cancer Invest (1996) 1.41
In vivo thermoluminescence dosimetry dose verification of transperineal 192Ir high-dose-rate brachytherapy using CT-based planning for the treatment of prostate cancer. Int J Radiat Oncol Biol Phys (2003) 1.41
Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol (2001) 1.39
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol (2000) 1.31
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol (2005) 1.28
Comparison of calibration procedures for 192Ir high-dose-rate brachytherapy sources. Int J Radiat Oncol Biol Phys (1999) 1.25
Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol (1994) 1.19
Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol (2001) 1.16
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer (1994) 1.13
Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features. Lung Cancer (2004) 1.12
Anatomy-based three-dimensional dose optimization in brachytherapy using multiobjective genetic algorithms. Med Phys (1999) 1.12
Isolation of a mouse Golgi mannosidase cDNA, a member of a gene family conserved from yeast to mammals. J Biol Chem (1994) 1.11
Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer (2001) 1.07
Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol (2003) 1.03
Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol (2001) 1.02
Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study. Oncology (1998) 1.00
Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials. Semin Oncol (1994) 0.99
Response of malignant thymoma to erlotinib. Ann Oncol (2008) 0.99
Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Lett (2002) 0.95
CT imaging based digitally reconstructed radiographs and their application in brachytherapy. Phys Med Biol (2000) 0.95
[Radiotherapy in Langerhans-cell histiocytosis. 2 case reports and review of the literature]. Rontgenpraxis (2000) 0.93
On the use of HDR 60Co source with the MammoSite radiation therapy system. Med Phys (2008) 0.92
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol (2007) 0.92
Greek adolescents, fitness, fatness, fat intake, activity, and coronary heart disease risk. Arch Dis Child (2004) 0.92
BRCA1 mutation analysis in breast/ovarian cancer families from Greece. Hum Mutat (2000) 0.91
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat (2008) 0.91
Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site. A Hellenic Cooperative Oncology Group Study. Ann Oncol (1992) 0.91
Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med (1998) 0.89
Effect of thickness on the sealing ability of some root canal sealers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1995) 0.89
Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Cancer Chemother Pharmacol (2012) 0.89
Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol (2002) 0.89
A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer (1996) 0.89
Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol (1996) 0.89
Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol (2004) 0.88
Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-Operative Oncology Group Phase II Study. Oncology (1998) 0.88
Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer (2007) 0.88
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety. Med Oncol (2006) 0.88
Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data. Anticancer Res (2006) 0.87
Multiobjective anatomy-based dose optimization for HDR-brachytherapy with constraint free deterministic algorithms. Phys Med Biol (2002) 0.87
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol (2010) 0.86
Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. Anticancer Res (2002) 0.86
Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer: the DEGRO-QUIRO trial. Strahlenther Onkol (2013) 0.86
Autoactivation of source dwell positions for HDR brachytherapy treatment planning. Med Phys (2000) 0.86
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study. Cancer Invest (2000) 0.86
Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer (2006) 0.85
Long-term survival data and prognostic factors of a complete response to chemotherapy in patients with head and neck cancer treated with platinum-based induction chemotherapy: a Hellenic Co-operative oncology Group study. Med Pediatr Oncol (1997) 0.85
Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer. Ann Oncol (2012) 0.85
Cyclin D1, EGFR, and Akt/mTOR pathway. Potential prognostic markers in localized laryngeal squamous cell carcinoma. Strahlenther Onkol (2013) 0.85
Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol (1997) 0.84
Squamous cell carcinoma antigen, circulating immune complexes, and immunoglobulins in monitoring squamous cell carcinoma of head and neck: a study of the hellenic co-operative oncology group (HeCOG). Am J Clin Oncol (1999) 0.84
Management of the clinically negative neck (N0) of supraglottic laryngeal carcinoma: a systematic review. Eur J Surg Oncol (2008) 0.84